On Oct. 22, Roche reported 7% growth at constant exchange rates (8% pharma, 5% diagnostics) in the third quarter, and management maintained full-year guidance for mid-single-digit sales and high-single-digit core EPS growth, also at constant rates. Shares traded flat.
Roche and its innovative US arm Genentech have a solid history of generating blockbuster therapies in oncology, and Roche's pipeline is full of novel candidates, with a particularly large late-stage pipeline.
Roche's immuno-oncology drug Tecentriq was launched third to market behind Bristol's Opdivo and Merck's Keytruda, raising questions about Roche's innovation.
|
Metric
|
ROP
|
MRK
|
ABBV
|
|---|---|---|---|
Price/Earnings (Normalized) | 21.85 | 45.87 | 26.24 |
Price/Book Value | 9.56 | 8.67 | — |
Price/Sales | 5.01 | 5.49 | 7.86 |
Price/Cash Flow | 15.70 | 16.49 | 21.64 |
|
Metric
|
ROP
|
MRK
|
ABBV
|
|---|---|---|---|
Quick Ratio | 0.80 | 0.71 | 0.49 |
Current Ratio | 1.23 | 1.32 | 0.81 |
Interest Coverage | 13.49 | 4.28 | 3.89 |
|
Metric
|
ROP
|
MRK
|
ABBV
|
|---|---|---|---|
Return on Assets (Normalized) | 15.81% | 6.27% | 14.29% |
Return on Equity (Normalized) | 48.77% | 16.68% | — |
Return on Invested Capital (Normalized) | 23.90% | 9.82% | 32.02% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|VmQ!?>Z | LOCK|>J | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|y%wyHW | LOCK|&C | $644B | |||
| AbbVie Inc
ABBV
| LOCK|><<gTb | LOCK|gq | $504B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|lJLd$fKt | LOCK|dXM | $380B | |||
| Merck & Co Inc
MRK
| LOCK|<pk&^<x | LOCK|&#w | $363B | |||
| Novartis AG ADR
NVS
| LOCK|Fp<JGd? | LOCK|ltP | $297B | |||
| AstraZeneca PLC
AZN
| LOCK|Rd>%?G&p | LOCK|%Q | $270B | |||
| Amgen Inc
AMGN
| LOCK|<#>#Nj@$ | LOCK|^xF | $242B | |||
| Gilead Sciences Inc
GILD
| LOCK|<^#Vp&N | LOCK|Sw | $195B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|CWJ<lR | LOCK|Db | $176B |
United States